Confident GSK sticks with plan going into 2022

9 February 2022

Presenting an upbeat set of financial results, the company’s first since refusing a £50 billion ($68.4 billion) offer for its consumer health unit, GlaxoSmithKline (LSE: GSK) said it took in £34.1 billion sales in 2021, £9.5 billion of which came in the final quarter.

Total operating profit came in at £6.2 billion, £895 million in the fourth quarter, making earnings per share (EPS) of 87.6 pence for the year and 15 pence for the quarter, higher than analysts had predicted.

The firm’s pharmaceuticals division brought in £17.7 billion, with sales of Xevudy (sotrovimab), an antibody treatment for COVID-19, contributing almost a billion pounds, mostly in the final quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK